Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06574269 · ClinicalTrials.gov registry record · Phase 2
A Study on TLC590 for Managing Postsurgical Pain
A Phase 2 study of Postsurgical Pain Management, sponsored by TLC Biopharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06574269: Recruiting Phase 2 study of Postsurgical Pain Management, sponsored by TLC Biopharmaceuticals.
NCT06574269 is a Phase 2 study of Postsurgical Pain Management that is actively recruiting participants, run by TLC Biopharmaceuticals. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06574269, a Phase 2 study of Postsurgical Pain Management, is actively recruiting participants, sponsored by TLC Biopharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.
Conditions Studied
Interventions
- DRUG TLC590
Study Locations (2)
Texas
- First Surgical Hospital - Bellaire
- Memorial Hermann Village - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT06574269 shows while recruiting
NCT06574269 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Postsurgical Pain Management appearing as the primary indexed condition, and to 1 intervention - of which TLC590 is the first listed.
NCT06574269 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06574269 about?
NCT06574269 is a clinical study titled "A Study on TLC590 for Managing Postsurgical Pain". This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunio...
What is the current status of trial NCT06574269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-09-30. Estimated completion is 2026-08.
What conditions does trial NCT06574269 study?
This clinical trial studies the following conditions: Postsurgical Pain Management.
What interventions are being tested in trial NCT06574269?
The interventions under investigation include: TLC590 (DRUG).
Who is sponsoring clinical trial NCT06574269?
This trial is sponsored by TLC Biopharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06574269 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postsurgical Pain Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06574269's enrollment target sits among peer trials
120 569th of 2000 higher than 1,384 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI